Levamisole immunotherapy of experimental transitional cell carcinoma.
Levamisole, in doses comparable to those under clinical investigation, was shown to significantly (P less than 0.02) delay the onset of transplanted transitional cell carcinoma of C3H mice. The growth of transplanted tumors was inhibited and animal survival prolonged with Levamisole treatment. Further progress in the immunotherapy of transitional cell carcinoma may be aided by such models.
D000818:Animals; D002295:Carcinoma, Transitional Cell / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D007167:Immunotherapy; D007978:Levamisole / Q000276:immunology / Q000627:therapeutic use*; D051379:Mice; D008809:Mice, Inbred C3H; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000276:immunology / Q000473:pathology / Q000628:therapy; D013997:Time Factors
D007978:Levamisole